证券代码：603998 证券简称：方盛制药 公告编号：2025-080 湖南方盛制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每股分配比例 A股每股现金红利0.15元 一、通过分配方案的股东会届次和日期 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交 易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者 可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分 公司保管，待办理指定交易后再进行派发。 本次利润分配方案经公司2025年5月20日的2024年年度股东大会审议通过，授权董事会办理中期利润分 配相关事宜，并经公司2025年8月27日召开第六届董事会第三次会议审议通过。 二、分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上 ...

证券日报网讯 9月11日晚间，方盛制药发布公告称，2025年半年度利润分配方案为A股每股现金红利 0.15元（含税），股权登记日为2025年9月17日，除权（息）日及现金红利发放日均为2025年9月18日。 （文章来源：证券日报） ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-081 湖南方盛制药股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体 接待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，湖南方盛制药股份有限 公司（以下简称"公司"）将参加由湖南证监局、湖南省上市公 司协会与深圳市全景网络有限公司联合举办的"资本聚三湘 楚 光耀新程——2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会"活动，现将相关事项公告如下： 湖南方盛制药股份有限公司董事会 2025年9月12日 第 1 页，共 1 页 本次活动将采用网络远程的方式举行，投资者可登录"全景 路演"网站（https://rs.p5w.net），或关注微信公众号：全景财经， 或下载全景路演 APP，参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:0 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-080 湖南方盛制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/17 | － | 2025/9/18 | 2025/9/18 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东 大会审议通过，授权董事会办理中期利润分配相关事宜，并经公 司 2025 年 8 月 27 日召开第六届董事会第三次会议审议通过。 二、 分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登 记 ...

Core Insights - The stock price of Fangsheng Pharmaceutical has decreased by 2.01% on September 9, trading at 11.21 CNY per share with a market capitalization of 4.922 billion CNY [1] - The company has experienced a year-to-date stock price increase of 10.33%, but has seen a decline of 2.94% over the last five trading days [1] Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million CNY, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 623 million CNY, with 418 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders has increased to 33,100, with an average of 13,245 circulating shares per shareholder, a slight decrease of 0.36% [2] - The top three circulating shareholders include ICBC Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed Fund, which increased its holdings by 500,000 shares to 5 million [3]

Market Overview - The overall market showed a downward trend with the Wind All A Index falling by 2.02% to 5938.15 points, while the Shanghai Composite Index decreased by 1.25% to 3765.88 points [7][8] - The ChiNext Index dropped by 4.25% to 2776.25 points, and the Sci-Tech 50 Index fell by 6.08% to 1226.98 points, indicating a significant decline in the hard technology sector [7][8] - In terms of market capitalization, the Shanghai 50 Index decreased by 1.71% to 2910.47 points, while the CSI 300 Index fell by 2.12% to 4365.21 points [8] Economic Insights - The People's Bank of China announced a 10 billion yuan reverse repurchase operation on September 5, 2025, with a term of three months [14][15] - On the same day, the central bank conducted a net withdrawal of 203.5 billion yuan from the market [16][17] - A joint meeting between the Ministry of Finance and the People's Bank of China was held to ensure better implementation of fiscal and monetary policies [18][19] Industry Dynamics - The Beijing-Tianjin-Hebei ultra-high voltage direct current transmission project is expected to commence full construction by the end of September 2025, with an investment of 17.178 billion yuan [25] - The third Changsha International Engineering Machinery Exhibition in Malaysia resulted in 11 companies signing contracts worth over 2 billion yuan [26][28] - Canalys reported a 12% year-on-year increase in PC shipments in mainland China for Q2 2025, with Apple leading the market growth [29][30] Company Updates - Haikang Technology (002653.SZ) received approval for clinical trials of its innovative drug HSK47388 for autoimmune diseases [31][32] - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary obtained clinical trial approval for a traditional Chinese medicine product aimed at treating postpartum complications [33][34]

Group 1 - US stock markets saw collective gains, with the Dow Jones up 0.77%, S&P 500 up 0.83%, and Nasdaq up 0.98%. Notable gains were seen in chip stocks, with Western Digital rising over 5% and Micron Technology up over 4% [3] - International precious metal futures generally declined, with COMEX gold futures down 0.91% at $3602.40 per ounce and COMEX silver futures down 1.77% at $41.32 per ounce [4] - European stock indices closed mixed, with Germany's DAX up 0.74% at 23770.33 points, France's CAC40 down 0.27% at 7698.92 points, and the UK's FTSE 100 up 0.42% at 9216.87 points [5] Group 2 - The People's Bank of China announced a 10 trillion yuan reverse repurchase operation on September 5, 2025, to maintain liquidity in the banking system [6] - The Ministry of Industry and Information Technology and the State Administration for Market Regulation issued the "Action Plan for Stable Growth of the Electronic Information Manufacturing Industry 2025-2026," targeting an average growth rate of around 7% for major electronic manufacturing sectors [7] - The State Council issued opinions on unleashing the potential of sports consumption, aiming for the sports industry to exceed 7 trillion yuan by 2030 [8] Group 3 - ByteDance reported the dismissal of 100 employees for violations, with 8 individuals suspected of criminal activity handed over to judicial authorities [13] - Huawei launched the new Mate XTs foldable smartphone, featuring the HarmonyOS 5 and a Kirin 9020 chip, with prices ranging from 17,999 to 21,999 yuan [14] - Agricultural Bank of China reached a market capitalization of 2.55 trillion yuan, surpassing Industrial and Commercial Bank of China for the first time [20]

Core Viewpoint - Fangsheng Pharmaceutical announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a gynecological hemostatic and analgesic granule project, marking a significant step in its drug innovation efforts [1] Group 1 - The clinical trial approval was granted on September 3, 2025, indicating the company's progress in drug development [1] - The project focuses on gynecological applications, which may address specific medical needs in this area [1]

Economic News - The Ministry of Industry and Information Technology and the Ministry of Finance have issued the "Action Plan for Stable Growth in the Electronic Information Manufacturing Industry for 2025-2026," emphasizing the importance of this sector for national economic stability and security [1] - The first central document from the national carbon market signals urgent need for corporate ESG disclosures, with 2,523 A-share companies having disclosed their 2024 ESG reports, representing a disclosure rate of 46.49% [1] - President Trump is set to host a dinner at the White House focusing on artificial intelligence, following a public event led by First Lady Melania Trump aimed at engaging students in AI [1] - The Federal Reserve's latest Beige Book indicates a potential for interest rate cuts, with market expectations for a 25 basis point cut in September rising to 96.6% [1] - Wall Street anticipates price increases for the upcoming iPhone 17, following Apple's commitment to invest $100 billion in U.S. manufacturing over the next four years [1] Company Insights - Kobot announced plans to acquire a 60% stake in Shanghai Kobot Intelligent Technology for 345 million yuan, focusing on automotive intelligent central computing platforms [5] - Southeast Network Framework won a bid for a project in Hangzhou with a contract value of approximately 1.686 billion yuan [5] - Yongzhen Co. has formed a partnership with a leading humanoid robot company to supply precision aluminum alloy components, although this is not expected to significantly impact short-term performance [5] - Fangsheng Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine for postpartum complications [6] - Tianenkang has received a notice of acceptance for the registration application of Dienogest tablets, which are used to treat endometriosis [6] Industry Ratings - China National Offshore Oil Corporation reported a revenue of 207.608 billion yuan for H1 2025, a decrease of 8% year-on-year, with net profit down 12.8% to 69.533 billion yuan [7][8] - The company managed to increase oil production by 4.48% to 296.1 million barrels and natural gas production by 11.97% to 516.2 million barrels, despite a 14.58% drop in Brent crude prices [8][9] - The company is focusing on exploration to secure oil and gas reserves, achieving significant discoveries in both domestic and international projects [9][10] - Shanghai Airport reported a revenue of 6.353 billion yuan for H1 2025, a year-on-year increase of 4.78%, with a notable rise in passenger throughput [11][12] - Non-aeronautical revenue growth was slower than expected, with total non-aeronautical income of 3.437 billion yuan, reflecting challenges in the duty-free segment [13][14]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-079 湖南方盛制药股份有限公司 关于控股子公司中药创新药研发项目获得药物临床 试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 9 月 3 日，湖南方盛制药股份有限公司（以下简称 "公司"或"方盛制药"）控股子公司广东方盛融科药业有限公 司（以下简称"方盛融科"）中药创新药研发项目妇科止血消痛 颗粒收到国家药品监督管理局核准签发的《药物临床试验批准通 知书》。现将相关情况公告如下： 一、药物的基本情况 药物名称：妇科止血消痛颗粒 剂型：颗粒剂 注册分类：中药 1.1 类 申请事项：临床试验 受理号：CXZL2500039 审批结论：根据《中华人民共和国药品管理法》及有关规定， 经审查，2025 年 6 月 12 日受理的妇科止血消痛颗粒符合药品注 册的有关要求，在进一步完善临床试验方案的基础上，同意本品 开展 II、III ...